BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Crit Care Med. Dec 9, 2025; 14(4): 108907
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.108907
Table 1 Calculation of 4C Mortality Score
Variable
4C Mortality Score
Age (years)
    < 50-
    50-59+2
    60-69+4
    70-79+6
    ≥ 80+7
Sex at birth
    Female-
    Male+1
1Number of comorbidities
    00
    1+1
    ≥ 2+2
Respiratory rate (breaths/minute)
    < 20-
    20-29+1
    ≥ 30+2
Peripheral oxygen saturation on room air (%)
    ≥ 92-
    < 92+2
Glasgow coma scale score
    15-
    < 15+2
Urea (mmol/L)
    < 7-
    7-14+1
    > 14+3
C reactive protein (mg/L)
    < 50-
    50-99+1
    ≥ 100+2
Table 2 Baseline characteristics of all patients stratified by hospital outcome, n (%)

All patients, n = 140
Alive, n = 121
Died, n = 19
P value
Age, years (mean ± SD)55.6 ± 16.853.3 ± 16.670.1 ± 9.6< 0.001
Sex0.03
Male87 (62.1)71 (81.6)16 (18.4)
Female53 (37.9)50 (94.3)3 (5.7)
No of comorbidities0.03
062 (44.3)59 (95.2)3 (4.8)
141 (29.3)33 (80.5)8 (19.5)
≥ 237 (26.4)29 (78.4)8 (21.6)
Process measures
Prone positioning0.57
No58 (41.4)49 (85.5)9 (15.5)
Yes82 (58.6)72 (87.8)10 (12.2)
Mechanical ventilation0.009
No89 (63.6)82 (92.1)7 (7.9)
Yes51 (36.4)39 (76.5)12 (23.5)
NIV + HFNP0.15
No50 (35.7)46 (92.0)4 (8.0)
Yes90 (64.3)75 (83.3)15 (16.7)
Vasopressors0.03
No97 (69.3)88 (90.7)9 (9.3)
Yes43 (30.7)33 (76.7)10 (23.3)
CRRT0.69
No138 (98.6)120 (87.0)18 (13.0)
Yes2 (1.4)1 (50.0)1 (50.0)
COVID specific treatment
Antiviral agents0.57
No58 (41.4)49 (84.5)9 (15.5)
Yes82 (58.6)72 (87.8)10 (12.2)
Monoclonal antibodies0.16
No109 (77.9)91 (83.5)18 (16.5)
Tocilizumab30 (21.4)29 (96.7)1 (3.3)
Sotrovimab1 (0.7)1 (100)0 (0)
Baricitinib0.53
No97 (69.3)85 (87.6)12 (12.4)
yes43 (30.7)36 (83.7)7 (16.3)
Length of stay, days
ICU, median and [IQR]5.9 [3.2-12.8]5 [2.8-11.2]13 [9.8-18.3]0.004
Hospital, median and [IQR]13.2 [7.7-22.6]11.9 [7.3-21.9]18.4 [14.1-22.3]0.09
Table 3 Physiological and laboratory parameters of all patients stratified by hospital outcome

All patients, n = 140
Alive, n = 121
Died, n = 19
P value
At hospital admission
Respiratory rate (breath/minute)28.8 ± 9.829.4 ± 10.225.4 ± 6.10.10
Peripheral oxygen saturation on room air (%)92.6 ± 7.392.2 ± 7.794.8 ± 2.70.14
Glasgow coma scale score14.7 ± 1.114.7 ± 1.214.6 ± 0.80.55
Urea (mmol/L)6.8 ± 5.06.4 ± 4.58.9 ± 7.40.048
C reactive protein (mg/L) [IQR]75 [41-121]74 [40-125]89 [42-107]0.81
At ICU admission
Respiratory rate (breath/minute)28.1 ± 9.528.2 ± 9.526.9 ± 9.30.56
Peripheral oxygen saturation on room air (%)93.4 ± 3.993.5 ± 4.193.2 ± 2.80.75
Glasgow coma scale score12.9 ± 4.312.9 ± 4.413.3 ± 3.80.72
Urea (mmol/L)7.2 ± 4.46.8 ± 4.19.6 ± 5.40.01
C reactive protein (mg/L) [IQR]75 [33-125]64 [31-124]100 [71-134]0.09
Table 4 Predictive scores of all patients stratified by hospital outcome

All patients, n = 140
Alive, n = 121
Died, n = 19
P value
Mortality prediction scores
4C Mortality Score at hospital admission7.6 ± 4.27.2 ± 4.210.6 ± 2.7< 0.001
4C Mortality Score at ICU admission8.4 ± 4.27.8 ± 4.112.1 ± 2.6< 0.0001
APACHE II12.9 ± 5.412.3 ± 5.316.9 ± 4.50.0004
APACHE III50.7 ± 18.048.1 ± 16.767.2 ± 17.5< 0.0001
Table 5 Predictive accuracy of 4C mortality and Acute Physiology and Chronic Health Evaluation scores

AUROC
95%CI
4C Mortality Score at hospital admission0.750.65-0.84
4C Mortality Score at ICU admission0.800.71-0.88
APACHE II0.750.65-0.85
APACHE III0.790.69-0.90
Table 6 Optimal cut-off value for the four predictive scores

Cut-off value
Sensitivity
Specificity
AUROC
95%CI for cut-off value
Hospital 4C mortality90.740.720.737.2-10.8
ICU 4C mortality100.840.720.788.9-11.1
APACHE II140.680.670.6811.8-16.2
APACHE III560.790.730.7652.0-60.0
Table 7 Comparison of mortality rates across intensive care unit 4C score risk groups, n (%)
Risk groups
Total, n = 140
Alive, n = 121
Died, n = 19
Low (0-3)15150
Intermediate (4-8)59581 (1.7)
High (9-15)574116 (28.1)
Very high (16-21)972 (22.2)
Table 8 Comparison with previous studies
Ref.
Study design
Sample size
Mortality%
4C Mortality Score calculated at
Comparison
AUROC1
95%CI
Knight et al[2], United KingdomMulticenter prospective observational2236130.9Hospital admissionDerivation and validation0.770.76-0.77
Covino et al[12], ItalySingle centre retrospective21020Hospital admissionCOVID-GRAM, qCSI, NEWS0.790.73-0.85
Wellbelove et al[10], United KingdomExploratory analysis5311Hospital admissionCURB-65, CRB-65, qSOFA, NEWS0.830.71-0.95
Kuroda et al[11], JapanMulticenter retrospective69334.4Hospital admissionRISE-UP, A-DROP, REMS0.840.80-0.88
Jones et al[13], CanadaMulticenter retrospective95923Hospital admission4C score in wave1, 2 and 30.770.74-0.80
Lombardi et al[3], FranceMulticenter retrospective1434335.3Hospital admission32 scores0.780.77-0.79
Vicka et al[6], LithuaniaSingle centre retrospective24941.4Hospital admissionAPACHE II, SOFA, SAPS0.750.69-0.81
Mohammad et al[8], Saudi ArabiaMulticenter retrospective5066.1Hospital admissionExternal validation0.900.85-0.95
Durie et al[5], AustraliaMulticenter prospective observational149213.2ICU admissionAPACHE II0.790.68-0.90
Altreby et al[4], Saudi ArabiaSingle centre retrospective149337.9ICU admissionExternal validation0.810.79-0.83
Ocho et al[9], JapanMulticenter retrospective20610.1Hospital admissionA-DROP, CURB-65, SOFA0.840.76-0.92
Our studySingle centre retrospective14013.6Hospital admission, ICU admissionAPACHE II, APACHE III0.75, 0.800.65-0.84, 0.71-0.88